Recent developments include strategic repositioning, arbitration confirming rights to the Net Force franchise, collaborations to validate diagnostic devices, and financial updates including bridge funding.

• NovelStem announced material developments and strategic repositioning of the company in May 2025 [N1].
• An arbitration confirmed NovelStem's joint venture rights to exploit the 'Tom Clancy's Net Force' franchise globally across multiple media formats in July 2023 [N2].
• NovelStem reported 2022 results highlighting focus on a patented genetic platform technology for anti-cancer therapies in March 2023 [N3].
• NovelStem's affiliate NewStem announced a collaboration to validate its software diagnostic device for oncology indications and therapies in December 2022 [N4].
• NovelStem secured commitment for up to $600,000 in bridge funding and provided a financial update in October 2022 [N5].
• NovelStem announced FDA pre-submission and EMA in vitro diagnostic device filing for a diagnostic device by 30%-owned NewStem in April 2022 [N6].
• NovelStem reviewed efforts to maximize value from legacy entertainment assets in February 2022 [N7].
• NovelStem announced NewStem was selected by Illumina for its Global Illumina Accelerator in September 2021 [N8].

NovelStem holds a significant financial interest in a unique stem cell-based biotechnology platform with potential applications in oncology diagnostics and therapeutics. The company's retained rights to future licensing revenues from the technology license originally held by NewStem could provide value if successfully commercialized by licensees. The company's strategic repositioning and collaborations to validate diagnostic devices indicate ongoing efforts to maximize asset value. The sale of the NetCo interest reduced debt and litigation exposure, potentially improving financial stability. NovelStem's low operating expenses and reliance on consultants may allow for lean operations while pursuing monetization opportunities.

NovelStem faces significant challenges including the liquidation of its biotech subsidiary NewStem, which ceased operations due to inability to raise funds. The company currently has no operating revenue or cost of revenue and depends entirely on earnings and cash from investments and licensing rights. Liquidity ratios as of March 31, 2026, show current liabilities vastly exceeding current assets, indicating financial stress. The biotech technology license has reverted to Yissum, limiting NovelStem's direct control and operational involvement. The competitive and regulatory environment for biotech products is complex and rapidly evolving, posing risks to future monetization. The company has no employees and relies on consultants, which may limit operational capacity.

NovelStem's moat is primarily based on its equity interest in proprietary stem cell-based biotechnology technology developed by NewStem Ltd, which was derived from an exclusive worldwide license from Yissum Research Development Company and The New York Stem Cells Foundation. The technology platform focuses on oncology drug discovery and diagnostics using haploid human pluripotent stem cells, a niche and innovative area with limited direct competition. Additionally, NovelStem held rights to the Net Force entertainment franchise through a joint venture, though this interest was sold in 2025. The exclusivity of the licensed technology and the company's retained financial interest in future licensing provide some competitive advantage, but the liquidation of NewStem and the transfer of the license back to Yissum limit direct operational control. The biotech field is subject to rapid technological change and regulatory challenges, which may impact the durability of the moat.

• Liquidity Risk: As of March 31, 2026, NovelStem's current liabilities significantly exceed its current assets, with a current ratio of 0.02 and a cash ratio of 0, indicating potential challenges in meeting short-term obligations.
• Dependence on Licensing and Investments: NovelStem's business model depends on earnings and cash from its equity interests and licensing rights, with no direct operating revenue. The liquidation of NewStem and transfer of the license to Yissum limit direct control over the core technology assets.
• Regulatory and Competitive Risks: The biotech technology underlying NovelStem's assets is subject to extensive regulation by the FDA and other authorities, with no FDA-approved medical device currently. Rapid technological changes and competition may affect the commercial viability of the licensed technology.
• Operational Capacity: NovelStem has no employees and relies on consultants, which may constrain its ability to execute strategic initiatives and manage operations effectively.

• NovelStem International Corp. is a holding company whose principal asset is an approximate 31% equity interest in NewStem Ltd, an Israeli biotech company, and a 50% equity interest in NetCo Partners, a joint venture owning the Net Force entertainment franchise, though the NetCo interest was sold in May 2025 to settle litigation funding debt.
• NewStem was liquidated in October 2025, and the technology license reverted to Yissum Research Development Company, Hebrew University's technology transfer company, with NovelStem retaining a financial interest of up to $3,750,000 in any future licensing.
• NovelStem's business focus shifted from media to biotech with the acquisition of NewStem in 2018, which developed a patented genetic platform technology for anti-cancer therapies based on haploid human pluripotent stem cells.
• NewStem developed a discovery bio-platform for genome-wide screenings and oncology drug development, including a personalized diagnostic for early detection of chemotherapy resistance.
• NewStem's technology was based on an exclusive worldwide license from Yissum and The New York Stem Cells Foundation, with obligations to pay royalties on net sales and sublicense consideration.
• NewStem filed an FDA Pre-Submission and received a CE Mark from the European Medicines Agency for its in vitro diagnostic device, but does not have an FDA approved medical device.
• NovelStem owned a 30.51% equity interest in NewStem at liquidation; other shareholders included Yissum, Professor Benvenisty, Illumina Cambridge LTD, and management.
• NovelStem owned a 50% interest in NetCo, which owns the Net Force property rights across media including books, film, TV, and video games; the interest was sold in May 2025 to settle litigation funding liabilities.
• NovelStem currently conducts no other business and has no operating revenue or cost of revenue; it relies on earnings and cash from its investments and licensing rights.
• The company had net income of approximately $2.38 million for the year ended December 31, 2025, compared to a net loss of approximately $3.23 million in 2024.
• General and administrative expenses decreased from approximately $881,000 in 2024 to $239,000 in 2025, primarily due to lower bad debt expense, stock-based compensation, and professional fees.
• NovelStem does not currently have employees and relies on consultants for operations.
• The company secured up to $600,000 in bridge funding as of October 2022.
• NovelStem announced material developments and strategic repositioning in May 2025.
• An arbitration confirmed NovelStem's joint venture rights to exploit the 'Tom Clancy's Net Force' franchise globally across multiple media formats.
• NewStem announced collaborations to validate its software diagnostic device for oncology indications and therapies.
• NewStem was selected by Illumina for its Global Illumina Accelerator program.
• NovelStem's financial snapshot as of March 31, 2026, shows cash and equivalents of $1,106, current assets of $100,912, and current liabilities of $5,304,486, resulting in a current ratio of 0.02 and a cash ratio of 0, indicating liquidity challenges.